Key facts
- It has raised $170.6M; the latest was Early Stage VC ($92.0M) in Oct 2024.
- Notable investors include Forbion, Gilde Healthcare, Bioqube Ventures, HealthCap, Medicxi — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for SynOx Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for SynOx Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SynOx Therapeutics
Developer of humanized monoclonal antibodies intended to significantly improve the lives of people living with Tenosynovial giant cell tumors (TGCT) and other colony-stimulating factor 1 (CSF-1) and macrophage-mediated diseases. The company provides life-improving options to address the unmet clinical needs of people living with (TGCT)Tenosynovial giant cell tumors and other macrophage-mediated diseases, enabling patients to have a best-in-class treatment option that can significantly improve their quality of life.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2020
- Employees
- 11
- Website
- synoxtherapeutics.com/
- Ownership
- Privately Held (backing)
SynOx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SynOx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SynOx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.